Resources and Tools

CSL Behring provides the following resources and tools, designed to help you and your patients better understand von Willebrand disease (VWD) and its treatment.

For you and your practice

Surgery Dosing Calculator
Our unique Humate-P loading dose calculator makes determination of individualized loading doses of Humate-P fast, easy, and convenient.

VWF Densitometric Analysis
The densitometric analysis compares various VWF/FVIII concentrates and normal human plasma.

Educational Programs
Learn more about our wide array of educational seminars and continuing medical education programs.

Reimbursement Resource Center
CSL Behring provides a range of reimbursement services, including individual claims processing reviews, assistance in appeals, insurance investigations into product coverage, and prior approvals for therapies authorization. To speak with a representative, call the Reimbursement Answerline at 1-800-676-4266 Monday through Friday from 8 a.m. to 5 p.m. ET.

For your patients

Self Infusion Video
Watch this online video to help your patients learn to self-infuse Humate-P at home.

Other Resources

Pharmacy Program
This online educational module is designed for pharmacists in an effort to spread awareness of VWD and its signs, symptoms, and treatments.

P&T Commmunity
For more managed care and formulary information about Humate-P.
Note that you must be a confirmed P&T committee member to have access. If you'd like to check your status, request your log in codes, or register for the site, please send an e-mail to Tony Berberabe at tberberabe@medimedia.com

News and Events
Find out the latest news about bleeding disorders, treatments, and more from CSL Behring, and learn about upcoming educational and community events in which CSL Behring is participating.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.